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Summary
Background Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented 
in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective 
predictors of outcome in frail patients with advanced colorectal cancer.
Methods We undertook an open, 2 × 2 factorial trial in 61 UK centres for patients with previously untreated advanced 
colorectal cancer who were considered unﬁ t for full-dose chemotherapy. After comprehensive health assessment (CHA), 
patients were randomly assigned by minimisation to: 48-h intravenous ﬂ uorouracil with levofolinate (group A); 
oxaliplatin and  ﬂ uorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D). Treatment 
allocation was not masked. Starting doses were 80% of standard doses, with discretionary escalation to full dose after 
6 weeks. The two primary outcome measures were: addition of oxaliplatin ([A vs B] + [C vs D]), assessed with progression-
free survival (PFS); and substitution of ﬂ uorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change from 
baseline to 12 weeks in global quality of life (QoL). Analysis was by intention to treat. Baseline clinical and CHA data 
were modelled against outcomes with a novel composite measure, overall treatment utility (OTU). This study is 
registered, number ISRCTN21221452.
Findings 459 patients were randomly assigned (115 to each of groups A–C, 114 to group D). Factorial comparison of 
addition of oxaliplatin versus no addition suggested some improvement in PFS, but the ﬁ nding was not signiﬁ cant 
(median 5·8 months [IQR 3·3–7·5] vs 4·5 months [2·8–6·4]; hazard ratio 0·84, 95% CI 0·69–1·01, p=0·07). Replacement 
of ﬂ uorouracil with capecitabine did not improve global QoL: 69 of 124 (56%) patients receiving ﬂ uorouracil reported 
improvement in global QoL compared with 69 of 123 (56%) receiving capecitabine. The risk of having any grade 3 or 
worse toxic eﬀ ect was not signiﬁ cantly increased with oxaliplatin (83/219 [38%] vs 70/221 [32%]; p=0·17), but was higher 
with capecitabine than with ﬂ uorouracil (88/222 [40%] vs 65/218 [30%]; p=0·03). In multivariable analysis, fewer baseline 
symptoms (odds ratio 1·32, 95% CI 1·14–1·52), less widespread disease (1·51, 1·05–2·19), and use of oxaliplatin (0·57, 
0·39–0·82) were predictive of better OTU.
Interpretation FOCUS2 shows that with an appropriate design, including reduced starting doses of chemotherapy, 
frail and elderly patients can participate in a randomised controlled trial. On balance, a combination including 
oxaliplatin was preferable to single-agent ﬂ uoropyrimidines, although the primary endpoint of PFS was not met. 
Capecitabine did not improve QoL compared with ﬂ uorouracil. Comprehensive baseline assessment holds promise 
as an objective predictor of treatment beneﬁ t.
Funding Cancer Research UK and the Medical Research Council.
Introduction
Advanced colorectal cancer is the second most common 
cause of death from cancer in developed countries, after 
lung cancer.1,2 In the UK, the median age at death from 
advanced colorectal cancer is 77 years, with 60% of deaths 
occurring in patients older than 75 years and 42% in 
those older than 80 years.3 Frailty, whether or not related 
to the cancer diagnosis, is frequent in elderly patients.
Standard treatment for advanced colorectal cancer 
includes palliative chemotherapy, with an expanding 
range of treatment options. But the evidence supporting 
these treatments is from clinical trials that under-
represented elderly, frail, and especially frail elderly 
patients.4 Several pivotal trials were restricted to patients 
younger than 75 years;5–7 however, even without a formal 
upper age limit there are several impediments to the 
recruitment of elderly participants.8 Reports of outcomes 
in older4 or frailer9 patient subsets within these trials, 
although interesting, are limited by the fact that the 
participants were by deﬁ nition suﬃ  ciently robust to have 
been included in the trials in the ﬁ rst place, whereas 
many other patients were not.
In 2002, the UK Medical Research Council (MRC) noted 
that investigators of its ﬁ rst-line trial for advanced colo-
rectal cancer, FOCUS (Fluorouracil, Oxaliplatin, CPT11 
[irinotecan]: Use and Sequencing),10 despite permissive 
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entry criteria and no upper age limit, were recruiting 
patients with a median age of only 64 years. A survey of 
investigators showed that the 59 trial oncologists who 
responded, while recruiting 422 patients into FOCUS, had 
treated a further 715 patients oﬀ -trial during the same 
period, frequently using reduced-dose or single-agent 
schedules. The most common reasons cited for non-
inclusion of technically eligible patients were physicians’ 
concerns about the adverse eﬀ ects of standard-dose 
treatments, patients’ wishes to avoid toxic eﬀ ects, and an 
assumption that oral therapy would improve quality of life 
(QoL). We therefore designed FOCUS2 for patients with 
advanced colorectal cancer who were to receive 
chemotherapy, but for whom the treating oncologist 
considered standard full-dose regimens to be unsuitable.
Methods
Study design and patients
Three trial design innovations were used to make 
FOCUS2 suitable for the frail and elderly population to 
be studied. First, as is common in non-trial practice, 
cytotoxic drugs were started at below-standard doses; 
second, a comprehensive geriatric health assessment 
was used to identify factors that might aid future selection 
of patients or regimens; third, alongside standard 
outcome measures a composite measure of overall 
treatment utility (OTU) was devised, incorporating 
objective and subjective measures of beneﬁ t and harm. 
FOCUS2 was undertaken in 61 UK centres, recruiting 
patients between January, 2004, and July, 2006. To enter 
FOCUS2, the oncologist had ﬁ rst to conﬁ rm, stating 
reasons, that the patient was in his or her opinion not a 
candidate for standard full-dose combination therapy. 
Patients had to have histologically conﬁ rmed colorectal 
adenocarcinoma, with unidimensionally measurable 
inoperable advanced or metastatic disease, and a WHO 
performance status of 2 or better. Patients had to have 
received no previous systemic chemotherapy for 
metastases. There was no upper or lower age limit. 
Previous adjuvant chemotherapy was allowed if completed 
more than 4 months before randomisation; previous rectal 
chemo radiotherapy was allowed if completed more than 
1 month before randomisation. Patients were not excluded 
for medical comorbidity unless the condition was so severe 
as to preclude protocol treatment. However, the following 
criteria were required: white blood cell count 3×10⁹ per L or 
greater, platelet count 100×10⁹ per L or greater, serum 
bilirubin no more than three times the upper limit of 
normal (ULN), serum transaminases no more than 
2·5 times ULN, and glomerular ﬁ ltration rate (GFR) 30 mL 
per min or greater.
We obtained written consent after verbal explanation and 
a written information sheet had been given to the patient, 
with at least 24 h allowed for consideration. Thereafter, but 
before randomisation, a 117-item comprehensive health 
assessment (CHA) was done (webappendix pp 1–8). This 
assessment comprised four nurse-administered modules 
(physical para meters including timed 20-m walk,11 mini-
nutritional assess ment,12 mini-mental state examination,13 
and medical comorbidity14) and four patient-completed 
modules (activities of daily living,15 symptoms,16 anxiety or 
depression,17 and global QoL or health resources18).
FOCUS-2 was approved by national and institutional 
research ethics committees and undertaken by the MRC 
Clinical Trials Unit (CTU), with MRC Good Clinical 
Research Practice,19 and was overseen by an independent 
Trial Steering Committee. Conﬁ dential interim analyses 
were reviewed every year by an independent Data 
Monitoring Committee.
Randomisation and masking
Patients were randomly assigned in a 1:1:1:1 ratio by 
telephone with a computerised algorithm developed and 
maintained centrally at the MRC CTU. Randomisation 
was done by use of the method of minimisation stratiﬁ ed 
by clinician, WHO performance status, status of primary 
tumour (resected or not), and age. Treatment allocation 
was not masked. 
Procedures
Treatment was started with standard regimens but at 
80% of standard cytotoxic drug doses. Group A received 
levofolinate 175 mg 2-h intravenous infusion, ﬂ uorouracil 
320 mg/m² 5-min intravenous bolus, and ﬂ uorouracil 
2240 mg/m² 46-h intravenous infusion. The cycle was 
repeated every 14 days (FU regimen). This regimen is 
80% of the simpliﬁ ed LV5FU2 regimen used in 
FOCUS.10,20 Group B received levofolinate 175 mg/m² 
and oxaliplatin 68 mg/m² by concurrent 2-h intravenous 
infusion, ﬂ uorouracil 320 mg/m² 5-min intravenous 
bolus, and ﬂ uorouracil 1920 mg/m² 46-h intravenous 
infusion. The cycle was repeated every 14 days (OxFU 
regimen). This regimen is 80% of the simpliﬁ ed 
FOLFOX regimen in FOCUS.10,20 Group C received 
capecitabine 1000 mg/m² orally twice per day on 
days 1–15. The cycle was repeated every 21 days (Cap 
regimen). This regimen is 80% of the standard licensed 
schedule. Group D received oxaliplatin 104 mg/m² 
2-h intravenous infusion, and capecitabine 800mg/m² 
orally twice per day on days 1–15. The cycle was repeated 
every 21 days (OxCap regimen). This regimen is 80% of 
the standard XELOX regimen.21 In patients with GFR 
30–50 mL per min, oxaliplatin and capecitabine were 
further reduced by 25%.
Before each cycle, toxicity was scored with common 
terminology criteria for adverse events (version 3.0). 
Detailed management of side-eﬀ ects was speciﬁ ed; 
brieﬂ y, grade 1 and worse eﬀ ects were treated 
symptomatically; persisting grade 2 and worse toxicity at 
day 1 of the next treatment cycle incurred a 1-week delay. 
Cytotoxic doses were reduced by 20% after two delays, or 
one delay of 2 weeks or more. If grade 2 or worse 
transaminitis (>2·5 times ULN) developed during 
capecitabine therapy, treatment was held until recovery. 
See Online for webappendix
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For grade 3 hyperbilirubinaemia (>3 times ULN), all 
cytotoxic drugs were reduced by 50%. Oxaliplatin was 
omitted for persistent grade 2 and worse neurological 
toxic eﬀ ects. Compliance with capecitabine was assessed 
with patient diary cards and tablet returns.
A senior clinician assessment was scheduled after 
6 weeks, when doses could be escalated to 100% of 
standard doses (an increase of 25% of starting doses), 
provided that no grade 2 or worse non-haematological 
toxic eﬀ ects had occurred and that the patient assented. 
After week 12, radiological response was assessed with 
Response Evaluation Criteria In Solid Tumors (RECIST) 
criteria;22 the clinician assessed whether there had been 
clinical deterioration in the patient; the CHA was 
repeated (omitting the comorbidity and mental-state 
modules) and the patient was asked two additional 
questions: whether their treatment had been worthwhile 
and how much it had interfered with activities 
(webappendix pp 9–13).
Thereafter, patients without radiological or clinical 
evidence of deterioration could continue the same 
regimen, immediately or after a planned break, with 
reassessment every 12 weeks. In groups A and C, when 
progression occurred on the FU or Cap regimens, second-
line treatment was considered with the OxFU or OxCap 
regimens, respectively. Second-line therapy in groups B 
and D, and third-line therapy in all groups, was at the 
discretion of the physician.
Statistical analysis
The primary questions in the two factorial comparisons 
were: does oxaliplatin improve ﬁ rst-line progression-free 
survival (PFS; [A vs B] + [C vs D])?; and does substitution 
of ﬂ uorouracil with capecitabine improve global QoL 
([A vs C] + [B vs D])?
For the ﬁ rst question, PFS was deﬁ ned as time from 
randomisation to ﬁ rst progression or death from any 
cause, assessed by intention to treat. FOCUS2 was 
designed to detect a 3-month improvement in median PFS 
from 6 months to 9 months. For 90% power at the two-
sided 5% signiﬁ cance level, 460 patients were needed.
For the second question, the primary outcome was 
QoL improvement. This outcome was deﬁ ned as any 
increase between baseline and 12 weeks in the EORTC-
QLQ-C30 global QoL subscale, reported as a percentage 
of patients with baseline and 12-week data. In a previous 
MRC trial,23 40% of 117 patients reported improved 
global QoL with this criterion. Paired data from 
260 patients (57% of the total) would be suﬃ  cient to 
detect an increase from 40% to 60%, at the two-sided 
5% signiﬁ cance level, with 90% power. PFS was a 
secondary outcome for this comparison.
Secondary outcome measures for both comparisons 
included response rate (RR), toxic eﬀ ects, and overall 
survival (OS). For time-to-event endpoints, Kaplan-Meier 
curves were produced with patients alive and event-free 
being censored at the time last seen. Hazard ratios (HRs) 
Figure 1: Trial proﬁ le
FU=simpliﬁ ed LV5FU2 regimen of levofolinate, bolus ﬂ uorouracil, and 46-h infusion of ﬂ uorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. 
Cap=capecitabine. OxCap=oxaliplatin plus Cap. OxFp=oxaliplatin plus ﬂ uoropyrimidine (either ﬂ uorouracil or capecitabine). 
459 randomised
115 allocated to group A
111 started their 
allocated ﬁrst line: 
FU
111 started their 
allocated ﬁrst line: 
Cap
111 started their 
allocated ﬁrst line: 
OxCap
107 started their 
allocated ﬁrst line: 
OxFU
107 patients died at
time of analysis
105 patients died at
time of analysis
102 patients died at
time of analysis
97 patients died at
time of analysis
3 no treatment
1 received alternative 
treatment
6 no treatment
2 received alternative 
treatment
2 no treatment
2 received alternative 
treatment
3 no treatment
48 received
recommended 
second line: OxFp
42 received
recommended 
second line: OxFp
8 received 
irinotecan-based
salvage
19 received 
irinotecan-based
salvage
115 allocated to group C
14 received 
irinotecan-based
salvage
18 received 
irinotecan-based
salvage
114 allocated to group D115 allocated to group B
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and 95% CIs were calculated for each comparison and 
compared with stratiﬁ ed log-rank tests. RR and toxic 
eﬀ ects are reported as percentage of assessable patients 
and compared with χ² tests. We compared QoL 
improvement with the Mann-Whitney test, which allows 
for non-normality. Tests for heterogeneity were done for 
time-to-event outcomes and tests of interaction for all 
other outcomes. 
The novel composite measure OTU was devised to 
reﬂ ect whether, from the viewpoint of both patient and 
clinician and with use of both objective and subjective 
measures, the treatment had been worthwhile. OTU was 
scored at 12 weeks (webappendix p 14). Brieﬂ y, good OTU 
indicated no clinical or radiological evidence of disease 
progression, and no major negative treatment eﬀ ects in 
terms of toxicity or patient acceptability. Intermediate 
OTU signiﬁ ed either clinical deterioration but no negative 
treatment eﬀ ect, or a signiﬁ cant negative treatment eﬀ ect 
but no clinical deterioration. Poor OTU indicated both 
clinical deterioration and a major negative treatment 
eﬀ ect, or death.
We then investigated whether baseline clinico-
pathological and CHA data can help to predict the 
probability of a favourable OTU at 12 weeks. Categorical 
factors and continuous factors with predeﬁ ned cutoﬀ s 
for categories were treated as categorical, with all other 
variables regarded as continuous. Univariate analyses 
were ﬁ rst done, with ordinal logistic regression, to assess 
patients’ baseline characteristics and CHA data in relation 
to the OTU score at 12 weeks. All variables, irrespective 
of their univariate result, were then included in a 
multivariable analysis with backward stepwise ordinal 
logistic regression. Results are displayed with odds ratios 
(ORs) to show the odds of a worse outcome, with eﬀ ect 
size (Z value) and statistical signiﬁ cance (p value).
This study is registered, number ISRCTN21221452.
Role of the funding source
The sponsor of the study was the MRC which, as the 
parent body of the MRC CTU, was involved in the design, 
conduct, and analysis of the trial. The manufacturers of 
the drugs used in the study were not involved in the 
research. The corresponding author had full access to the 
data and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Figure 1 shows the trial proﬁ le. 411 of 459 (90%) patients 
had died at the time of ﬁ nal analysis. Baseline 
characteristics were well balanced between groups 
(table 1). Median age was 74 years (range 35–87), with 
199 (43%) patients older than 75 years and 60 (13%) older 
than 80 years. 98 (21%) patients had WHO performance 
status of 0, 227 (49%) a performance status of 1, and 
134 (29%) a performance status of 2. The reason for 
inclusion in FOCUS2 instead of a full-dose protocol was 
cited as frailty in 324 (71%) patients and advanced age 
in 311 (68%). However, dementia was uncommon: full 
baseline mini-mental health data were obtained in 
387 patients, of whom 374 (96%) scored within the 
normal range and only two (0·5%) fell within the range 
associated with dementia.
Group A Group B Group C Group D
Allocated ﬁ rst-line treatment FU OxFU Cap OxCap
Number allocated 115 115 115 114
Number started treatment 111 107 111 111
Dose escalation at 6 weeks
On study at 6 weeks 100 106 107 106
Dose escalated 47 (47%) 36 (34%) 39 (36%) 32 (30%)
Eligible for escalation but not escalated 31 (31%) 41 (39%) 30 (28%) 33 (31%)
Not escalated because of toxicity 16 (16%) 23 (22%) 23 (21%) 38 (36%)
Dose delivery during ﬁ rst 12 weeks of treatment
Increased at 6 weeks and sustained 20 (18%) 14 (13%) 11 (10%) 15 (14%)
Sustained starting dose 32 (29%) 32 (30%) 42 (38%) 40 (36%)
Further dose reduced or stopped 57 (51%) 59 (55%) 54 (48%) 46 (41%)
Higher dose than intended* 2 (2%) 2 (2%) 4 (4%) 10 (9%)
Data are number (%), unless otherwise indicated. FU=simpliﬁ ed LV5FU2 regimen of levofolinate, bolus ﬂ uorouracil, and 
46-h infusion of ﬂ uorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin 
plus Cap. *These patients had a dose increase earlier than the protocol-speciﬁ ed week 6 escalation point.
Table 2: Treatment received
Group A 
(n=115)
Group B 
(n=115)
Group C 
(n=115)
Group D 
(n=114)
Total 
(n=459)
Sex
Men 73 (63%) 69 (60%) 68 (59%) 68 (60%) 278 (61%)
Women 42 (37%) 46 (40%) 47 (41%) 46 (40%) 181 (39%)
Age (years)
Median 75 75 73 75 74
IQR 71–78 71–78 69–78 70–79 70–78
Range 46–86 35–87 49–84 45–85 35–87
WHO performance status
0 25 (22%) 23 (20%) 23 (20%) 27 (24%) 98 (21%)
1 58 (50%) 57 (50%) 58 (50%) 54 (47%) 227 (50%)
2 32 (28%) 35 (30%) 34 (30%) 33 (29%) 134 (29%)
Primary tumour site
Rectum 25 (22%) 30 (26%) 31 (27%) 34 (30%) 120 (26%)
Colon 90 (78%) 85 (74%) 84 (73%) 80 (70%) 339 (74%)
Primary tumour not resected 39 (34%) 40 (35%) 40 (35%) 40 (35%) 159 (35%)
Metastatic sites
No distant metastases 1 (1%) 2 (2%) 1 (1%) 1 (1%) 5 (1%)
Non-liver metastases 31 (27%) 25 (22%) 30 (26%) 26 (23%) 112 (24%)
Liver-only metastases 17 (15%) 14 (12%) 14 (12%) 22 (19%) 67 (15%)
Liver+other metastases 66 (57%) 74 (64%) 70 (61%) 65 (57%) 275 (60%)
Reason for entering FOCUS2
Advanced age alone 35 (30%) 28 (24%) 37 (32%) 35 (31%) 135 (29%)
Frailty/patient choice alone 37 (32%) 36 (31%) 35 (30%) 40 (35%) 148 (32%)
Both age and frailty/choice 43 (37%) 51 (44%) 43 (37%) 39 (34%) 176 (38%)
Data are number (%), unless otherwise indicated.
Table 1: Baseline patient characteristics
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419 (91%) patients were alive and receiving treatment 
6 weeks after starting treatment, and so were eligible for 
discretionary escalation to 100% of standard doses 
(table 2). Of these patients, 154 (37%) had dose escalation. 
Dose escalation was more frequent in patients allo-
cated single agent than combination therapy (p=0·01). 
Figure 2: Kaplan-Meier curves for PFS and OS for each main eﬀ ect comparison and hazard ratio plots to show tests for heterogeneity for each 
factorial comparison
(A) PFS by addition of oxaliplatin. (B) PFS by FU versus Cap. (C) OS by addition of oxaliplatin. (D) OS by FU versus Cap. PFS=progression-free survival. OS=overall 
survival. FU=simpliﬁ ed LV5FU2 regimen of levofolinate, bolus ﬂ uorouracil, and 46-h infusion of ﬂ uorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. 
Cap=capecitabine. OxCap=oxaliplatin plus Cap.
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Only 60 (14% of all patients starting treatment) sustained 
the higher dose to 12 weeks (table 2). 146 (33%) patients 
sustained the 80% standard starting dose to 12 weeks, 
whereas 215 (49%) needed a further dose reduction or 
stopped (table 2). Capecitabine compliance, assessed by 
tablet returns, was greater than 97% in the Cap (group C) 
and OxCap (group D) regimens (data not shown).
At the time of analysis 445 (97%) patients had had a 
PFS event (ﬁ gure 2A). PFS, measured by intention to 
treat, was the primary outcome measure for the factorial 
comparison of treatment with or without oxaliplatin; 
this comparison suggested some beneﬁ t of oxaliplatin 
but the ﬁ nding was not signiﬁ cant (ﬁ gure 2A; table 3). 
Factorial comparison of ﬂ uorouracil versus capecitabine 
showed no eﬀ ect on PFS (ﬁ gure 2B; table 3).
Paired baseline and 12-week QoL data were available in 
247 patients, with similar numbers in each group 
(table 3). QoL improvement was the primary outcome 
measure for the factorial comparison of ﬂ uorouracil 
versus capecitabine; this comparison showed no 
diﬀ erence between groups, with more than half of 
assessable patients reporting improved QoL in both 
groups (table 3). Factorial comparison of treatment with 
and without oxaliplatin was suggestive of a detrimental 
eﬀ ect with oxaliplatin regimens (table 3).
RR was assessed with RECIST criteria but only at 
12 weeks after randomisation. In the factorial com parisons, 
we recorded good evidence that oxaliplatin increased the 
RR (complete response plus partial response) and the rate 
of disease control (stable disease, complete response, and 
partial response; table 3). We noted no evidence that the 
substitution of ﬂ uorouracil with capecita bine had an eﬀ ect 
on response or disease control (table 3).
Factorial analysis showed no evidence of OS beneﬁ t with 
ﬁ rst-line oxaliplatin (ﬁ gure 2C). Similarly, factorial analysis 
showed no diﬀ erence in OS between ﬂ uorouracil and 
capecitabine (ﬁ gure 2D).
440 (96%) patients had complete data for toxic eﬀ ects. 
The overall risk of having a grade 3 or worse event during 
the ﬁ rst 12 weeks ranged from 27% of assessed patients 
(29 of 109) with the FU regimen to 43% (47 of 110) with the 
OxCap regimen (table 4). In the factorial comparisons, the 
use of oxaliplatin did not signiﬁ cantly increase the overall 
risk of toxic eﬀ ects, but we noted evidence of increased 
rates of diarrhoea, neurosensory toxicity, nausea, vomiting, 
and neutro penia, and a lower rate of hand-foot syndrome 
compared with no use of oxaliplatin (table 4). Compared 
with ﬂ uorouracil, capecitabine increased the overall risk of 
a grade 3 or worse event (p=0·03), and was speciﬁ cally 
associated with increased rates of nausea, vomiting, 
diarrhoea, anorexia, and hand-foot syndrome.
438 (95%) patients had complete data to allow scoring 
of OTU at 12 weeks, of whom 182 (42%) scored good, 
140 (32%) intermediate, and 116 (26%) poor. Better OTU 
Individual groups Factorial comparisons
Addition of oxaliplatin [A vs B] + [C vs D] Fluorouracil vs capecitabine [A vs C] + [B vs D]
A (FU) B (OxFU) C (Cap) D (OxCap) No oxaliplatin With oxaliplatin p Fluorouracil based Capecitabine based p
Number allocated 115 115 115 114 230 229 ·· 230 229 ··
Survival and response
Number started treatment 111 107 111 111 222 219 ·· 218 222 ··
RECIST response at week 12–14
Response rate: CR + PR (%)* 12 (11%) 41 (38%) 16 (14%) 36 (32%) 28 (13%) 77 (35%) <0·0001 53 (24%) 52 (23%) 0·83
Disease control: CR + PR + SD (%) 51 (46%) 76 (71%) 56 (50%) 72 (65%) 107 (48%) 148 (68%) <0·0001 127 (58%) 128 (58%) 0·90
Median PFS (months; IQR)† 3·5 
(2·8–6·2)
5·8
(3·2–7·6)
5·2
(2·8–6·7)
5·8
(3·3–7·4)
·· ·· ·· ·· ·· ··
HR (95% CI) ·· ·· ·· ·· Reference 0·84 (0·69–1·01) 0·07 Reference 0·99 (0·82–1·20) 0·93
Median OS (months; IQR) † 10·1
(5·1–17·3)
10·7
(5·7–17·2)
11·0
(5·4–18·0)
12·4
(5·8–18·0)
·· ·· ·· ·· ·· ··
HR (95% CI) ·· ·· ·· ·· Reference 0·99 (0·81–1·18) 0·91 Reference 0·96 (0·79–1·17) 0·71
Improved QoL at week 12–14
Complete QoL data 62 62 65 58 127 120 ·· 124 123 ··
Improved global QoL (%) 37 ( 60%) 32 (52%) 42 (65%) 27 (47%) 79 (62%) 59 (49%) 0·04 69 (56%) 69 (56%) 0·94
OTU score at 12 weeks
Assessable for OTU 109 107 111 111 220 218 ·· 216 222
Good (%) 38 (35%) 58 (54%) 41 (37%) 45 (41%) 79 (36%) 103 (47%) 0·003‡ 96 (44%) 86 (39%) 0·27‡
Intermediate (%) 37 (34%) 29 (27%) 33 (30%) 41 (37%) 70 (32%) 70 (32%) ·· 66 (31%) 74 (33%) ··
Poor (%) 34 (31%) 20 (19%) 37 (33%) 25 (23%) 71 (32%) 45 (21%) ·· 54 (25%) 62 (30%) ··
FU=simpliﬁ ed LV5FU2 regimen of levofolinate, bolus ﬂ uorouracil, and 46-h infusion of ﬂ uorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. 
RECIST=Response Evaluation Criteria In Solid Tumors. CR=complete response. PR=partial response. SD=stable disease. PFS=progression-free survival. OS=overall survival. QoL=quality of life. OTU=overall 
treatment utility. *Interaction test: Z=–1·18, p=0·238. †Interaction tests done for time-to-event endpoints (ﬁ gure 2) and OTU score. ‡χ² test for trend. 
Table 3: Main outcome measures
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was strongly associated with improved PFS and OS (both 
p<0·0001, log-rank trend test; data not shown). In the 
factorial comparisons, allocation to receive oxaliplatin 
was associated with better OTU (p=0·003), but we 
recorded no signiﬁ cant diﬀ erence in OTU with 
ﬂ uorouracil or capecitabine (table 3).
Univariate analysis was done with baseline 
clinicopathological variables, CHA variables, and treat-
ment allocation (ﬁ gure 3). The strongest predictors of 
12-week OTU were: WHO performance status, white 
blood cell count, EQ5D QoL score, overall symptom 
score, and allocation to oxaliplatin (all p<0·01; ﬁ gure 3). 
Group A 
(FU; N=109)
Group B 
(OxFU; N=109)
Group C 
(Cap; N=112)
Group D 
(OxCap; N=110)
Factorial comparisons
Addition of oxaliplatin Fluorouracil vs capecitabine
[A vs B] + [C vs D] p [A vs C] + [B vs D] p
Any toxicity
Grade ≥2 84 (77%) 81 (74%) 86 (77%) 94 (86%) 170 (77%) vs 175 (80%) 0·45 165 (76%) vs 180 (81%) 0·17
Grade ≥3 29 (27%) 36 (33%) 41 (37%) 47 (43%) 70 (32%) vs 83 (38%) 0·17 65 (30%) vs 88 (40%) 0·03
Nausea
Grade ≥2 8 (7%) 17 (16%) 15 (13%) 27 (25%) 23 (10%) vs 44 (44%) <0·0001 25 (12%) vs 42 (19%) 0·03
Grade ≥3 1 (1%) 2 (2%) 6 (5%) 5 (5%) 7 (3%) vs 7 (3%) 0·99 3 (1%) vs 11 (5%) 0·03
Vomiting
Grade ≥2 5 (5%) 13 (12%) 12 (11%) 21 (19%) 17 (8%) vs 34 (16%) 0·01 18 (8%) vs 33 (15%) 0·03
Grade ≥3 1 (1%) 2 (2%) 3 (3%) 3 (3%) 4 (2%) vs 5 (2%) 0·73 3 (1%) vs 6 (3%) 0·33
Anorexia
Grade ≥2 12 (11%) 15 (14%) 19 (17%) 26 (24%) 31 (14%) vs 41 (19%) 0·18 27 (12%) vs 45 (20%) 0·03
Grade ≥3 3 (3%) 3 (3%) 6 (5%) 4 (4%) 9 (4%) vs 7 (3%) 0·62 6 (3%) vs 10 (5%) 0·33
Stomatitis
Grade ≥2 12 (11%) 13 (12%) 6 (5%) 12 (11%) 18 (8%) vs 25 (11%) 0·25 25 (12%) vs 18 (8%) 0·24
Grade ≥3 2 (2%) 3 (3%) 1 (1%) 2 (2%) 3 (1%) vs 5 (2%) 0·47 5 (2%) vs 3 (1%) 0·46
Diarrhoea
Grade ≥2 20 (18%) 21 (19%) 23 (21%) 38 (35%) 43 (20%) vs 59 (27%) 0·06 41 (19%) vs 61 (28%) 0·03
Grade ≥3 5 (5%) 7 (6%) 10 (9%) 20 (18%) 15 (7%) vs 27 (12%) 0·05 12 (6%) vs 30 (14%) 0·003
Lethargy
Grade ≥2 41 (38%) 46 (42%) 40 (36%) 47 (43%) 81 (37%) vs 93 (43%) 0·21 89 (40%) vs 87 (39%) 0·88
Grade ≥3 8 (7%) 10 (9%) 15 (13%) 16 (15%) 23 (10%) vs 26 (12%) 0·63 18 (8%) vs 31 (14%) 0·06
Pain
Grade ≥2 17 (16%) 18 (17%) 24 (21%) 20 (18%) 41 (19%) vs 38 (17%) 0·74 35 (16%) vs 44 (20%) 0·30
Grade ≥3 9 (8%) 5 (5%) 11 (10%) 6 (6%) 20 (9%) vs 11 (5%) 0·10 14 (6%) vs 17 (8%) 0·61
Neurosensory
Grade ≥2 2 (2%) 10 (9%) 4 (4%) 15 (14%) 6 (3%) vs 25 (11%) 0·0005 12 (6%) vs 19 (9%) 0·21
Grade ≥3 0 (0%) 1 (1%) 0 (0%) 4 (4%) 0 (0%) vs 5 (2%) 0·02 1 (1%) vs 4 (2%) 0·18
HFS
Grade ≥2 1 (1%) 2 (2%) 24 (21%) 13 (12%) 25 (11%) vs 15 (7%) 0·10 3 (1%) vs 37 (17%) <0·0001
Grade ≥3 0 (0%) 0 (0%) 11 (10%) 2 (2%) 11 (5%) vs 2 (1%) 0·01 0 (0%) vs 13 (6%) 0·0001
Platelets
Grade ≥2 0 (0%) 2 (2%) 1 (1%) 2 (2%) 1 (0·5%) vs 4 (2%) 0·17 2 (1%) vs 3 (1%) 0·67
Grade ≥3 0 (0%) 1 (1%) 1 (1%) 1 (1%) 1 (0·5%) vs 2 (1%) 0·56 1 (0·5%) vs 2 (1%) 0·57
Anaemia
Grade ≥2 20 (18%) 21 (19%) 14 (13%) 18 (16%) 34 (15%) vs 39 (18%) 0·49 41 (19%) vs 32 (14%) 0·22
Grade ≥3 3 (3%) 3 (3%) 1 (1%) 2 (2%) 4 (2%) vs 5 (2%) 0·73 6 (3%) vs 3 (1%) 0·30
Neutropenia
Grade ≥2 6 (6%) 11 (10%) 3 (3%) 10 (9%) 9 (4%) vs 21 (10%) 0·02 17 (8%) vs 13 (6%) 0·42
Grade ≥3 3 (3%) 6 (6%) 2 (2%) 2 (2%) 5 (2%) vs 8 (4%) 0·39 9 (4%) vs 4 (2%) 0·15
Tests for interaction between the two treatment factors showed no evidence of an interaction (data not shown). FU=simpliﬁ ed LV5FU2 regimen of levofolinate, bolus 
ﬂ uorouracil, and 46-h infusion of ﬂ uorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. HFS=hand-foot syndrome. 
Table 4: Toxic eﬀ ects, weeks 1–12
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A B
All patients
Sex
Male
Female
WHO performance status
0
1
2
Number of disease sites
1
>1
Number of metastatic sites
1
2
≥3
Liver metastases
No
Liver only
Liver with other
WBC count (×10⁹/L)
≤10
>10
GFR (mL/min)
≥50
<50
Albumin (g/L)
≥30
<30
BMI (kg/m²)
19–25
25–30
<19 or >30
Arm circumference (cm)
<21
21–22
>22
Weight loss (kg)
<1 
1–3 
>3 
Not known
Anxiety
Normal
Borderline
Case
Depression
Normal
Borderline
Case
Addition of Ox
No Ox
Ox
FU vs Cap
FU
Cap
438
269
169
94
218
126
108
330
179
163
96
107
109
217
294
144
386
43
405
33
168
158
95
25
22
387
102
66
102
76
380
47
11
388
38
12
220
218
216
222
Age (years)
<70
70–72
73–75
76–78
≥79
EQ5D
<0·6
0·6–0·69
0·7–0·79
0·8–0·99
≥1·0
Overall symptom score*
<8
8–14·9
15–21·9
22–32·9
≥33
Nottingham ADL
<40
40–49
50–54
55–59
60
Charlson comorbidity
0
1
2
Mini mental health score
<25
25–29
≥30
Timed walk score†
<4
4–4·9
5–5·9
6–6·9
≥7
98
62
87
87
104
52
55
111
74
112
78
79
88
81
87
82
82
71
79
102
246
111
81
30
231
177
81
57
94
83
70
OTU distribution (%) Z value p valueOdds of a worse 
outcome (95% CI)
OTU distribution (%)N N Z value p valueOdds of a worse 
outcome (95% CI)
Good
Intermediate
Poor
0·2531·14
Reference                       ··                  ··
1·22 (0·87–1·73)
0·003–2·92
Reference                       ··                  ··
0·59 (0·42–0·84)
0·1101·601·42 (0·92–2·18)
0·2261·211·27 (0·86–1·88)
0·715
0·129
0·888
0·37
1·52
–0·14
Reference                       ··                  ··
1·11 (0·63–1·95)
1·42 (0·90–2·22)
0·96 (0·56–1·66)
0·129–1·520·77 (0·55–1·08)
0·443
0·409
–0·77
–0·83
Reference                       ··                  ··
0·85 (0·57–1·28)
0·82 (0·52–1·31)
0·0491·97
Reference                       ··                  ·· 
1·99 (1·00–1·15)
0·1461·45
Reference                       ··                  ·· 
1·55 (0·86–2·79)
0·0023·11
Reference                       ··                  ··
1·82 (1·25–2·64)
0·659
0·035
–0·44
2·11
Reference                       ··                  ··
0·89 (0·54–1·48)
1·59 (1·03–2·46)
0·374
0·015
0·89
2·43
Reference                       ··                  ··
1·20 (0·80–1·78)
1·76 (1·11–2·77)
0·5620·581·13 (0·75–1·69)
<0·00013·721·61 (1·25–2·06)
0·768–0·30
Reference                       ··                  ··
0·95 (0·66–1·35)
··                                      ··                  ··
0 20 40 60 80 100
0 20 40 60 80 100
0·147–1·450·94 (0·86–1·02)
per SD increase
0·2611·131·05 (0·96–1·14)
per SD increase
0·021–2·300·83 (0·70–0·97)
per 10 unit 
increase
<0·00014·62
1·36 (1·19–1·55)
per 10 unit 
increase
<0·0001–4·29
0·83 (0·76–0·90)
per 0·1 unit 
increase
0·223–1·22
0·90 (0·82–1·05)
per 10 year 
increase
0·280–1·080·96 (0·89–1·03)
per SD increase
Worse
Better
Worse
Better
Better
Worse
Worse
Better
Better
Worse
Worse
Better
Figure 3: Association of categorical factors (A) and continuous factors (B) associated with OTU outcome
Odds of a worse outcome is expressed with reference to the more normal state, or as an odds ratio proportional across all categories. OTU=overall treatment utility. WBC=white blood cell. 
GFR=glomerular ﬁ ltration rate. BMI=body-mass index. FU=simpliﬁ ed LV5FU2 regimen of levofolinate, bolus ﬂ uorouracil, and 46-h infusion of ﬂ uorouracil, repeated every 2 weeks. Ox=oxaliplatin. 
Cap=capecitabine. ADL=activities of daily living. *Mean EORTC QLQ-C30 symptom score. †Calculated as 100/time in s to walk 20 m. 
Articles
www.thelancet.com   Vol 377   May 21, 2011 1757
We recorded no evidence of interaction between the two 
treatment factors (p=0·209; data not shown).
Multivariable analyses (table 5) produced a potentially 
predictive model based on overall symptom score, 
presence of liver plus extrahepatic metastases, and 
treatment. WHO performance status and age were 
included for clinical relevance. On the basis of this 
model, a 70-year-old patient with performance status 
of 1, with both liver and extrahepatic metastases, whose 
overall symptom score is 60, treated with single-agent 
ﬂ uoropyrimidines, has a 61% (95% CI 45–76) probability 
of a poor OTU and only a 12% (5–20) probability of a 
good OTU. Conversely, an 80-year-old patient with 
performance status of 1 and a symptom score 0 and 
either extrahepatic-only or liver-only disease, treated 
with combination chemotherapy, has a 66% (56–77) 
probability of a good OTU and only 10% (5–14) 
probability of a poor OTU.
Discussion
This is the largest randomised controlled trial so far to 
have selectively recruited frail and elderly patients with 
advanced colorectal cancer (panel). With use of reduced 
starting drug doses, adapted for this population, 
combination chemotherapy including oxaliplatin seems, 
on balance, preferable to single-agent ﬂ uoropyrimidines, 
although the primary endpoint of PFS was not met. We 
did not, however, detect any advantage of capecitabine 
compared with ﬂ uorouracil.
FOCUS2 successfully recruited an elderly and frail 
population into a large national trial. Indeed, the trial 
proved so popular with patients and clinicians that it 
recruited well ahead of target, showing that age and 
frailty need not be barriers to research. The decision to 
start treatments at 80% of standard doses, although 
arbitrary, mimics common non-trial practice in frail 
elderly patients. Generally moderate rates of toxic eﬀ ects 
and good rates of improvement in QoL in all groups 
would seem to support this strategy, whereas the relatively 
low uptake of escalation at 6 weeks, and the fact that only 
14% of all patients sustained full-dose therapy to 12 weeks, 
supports the notion that the trial population was unsuited 
for full-dose therapy.
We introduced a novel composite endpoint, OTU, to 
assess the outcome of palliative chemotherapy, and 
explored the use of objective baseline evaluation to 
estimate the likelihood of a good or poor outcome with 
treatment. When conﬁ rmed and reﬁ ned with further 
studies, this approach could potentially provide valuable 
guidance for doctors and patients in the diﬃ  cult decisions 
between active or symptomatic care or, potentially, 
between active regimens. The interpretation of clinical 
trials, especially trials of palliative chemotherapy, often 
needs subjective synthesis of the objective data. Measures 
of eﬃ  cacy are weighed against toxic eﬀ ects, convenience, 
and other variables before deciding which treatment is 
best. For FOCUS2 we developed a simple composite 
endpoint of treatment outcome, OTU, to reﬂ ect both the 
doctor’s question: “In retrospect, am I glad I oﬀ ered this 
treatment?”; and the patient’s question: “Am I glad I 
accepted it?”. OTU combines clinical eﬃ  cacy (“Is my 
patient alive without disease progression?”), clinical 
tolerability (“Did we avoid causing major harm?”), and 
patient opinion (“Was my treatment worthwhile and 
acceptable?”). We encourage other research groups to 
adopt and reﬁ ne this patient-centred approach.
OTU proved useful in comparison of treatment groups, 
particularly when conventional endpoints were divergent. 
The addition of oxaliplatin signiﬁ cantly increased RR 
and suggested some improvement in PFS, although this 
Odds of a worse 
outcome (95% CI)
Z value p value
Overall baseline symptom score 1·32* (1·14–1·52) 3·79 <0·0001
Additional oxaliplatin 0·57 (0·39–0·82) –2·98 0·003
Liver with other metastases 1·51 (1·05–2·19) 2·22 0·026
WHO performance status 1·28 (0·96–1·70) 1·70 0·090
Age 1·00 (0·98–1·02) 0·14 0·887
Interaction between the two treatment factors was assessed (Z=–1·26, p=0·209). 
OTU=overall treatment utility. *This odds ratio relates to a 10-point change in the 
overall symptom score. 
Table 5: Factors associated with OTU outcome (multivariate analysis)
Panel: Research in context
Systematic review
Previous publications and international meeting abstracts were searched with Ovid 
Medline and American Society of Clinical Oncology databases to ﬁ nd previous reports of 
palliative chemotherapy in elderly and frail patients with advanced colorectal cancer. Until 
now, the major reports of survival data for elderly patients receiving palliative 
chemotherapy have come from subgroup analyses of older patients participating in 
standard full-dose trials,4 or from trials of full-dose chemotherapy in selected ﬁ t elderly 
patients.24 These analyses show that elderly patients selected for full-dose treatments 
achieve survival times similar to younger patients on the same treatments; however, they 
represent only a small and highly selected proportion of the elderly cancer population. 
Interpretation
FOCUS2 adds to the totality of evidence because it is the ﬁ rst large randomised trial in 
colorectal cancer to have been designed speciﬁ cally for frail elderly patients and to relate 
objective baseline measures of geriatric ﬁ tness with patient-related outcomes of 
chemotherapy. Survival, at a median of 11 months, is noticeably shorter than in 
contemporaneous standard trials. For example, during overlapping recruitment periods 
two other MRC trials, FOCUS and COIN, were running at many of the same centres as 
FOCUS2, accruing patients with a median age of 63 years, more than 90% of whom had 
WHO performance status 0–1, with median survival of 14–17 months.10,25,26 Meanwhile, in 
France, a selective trial using more intensive therapy achieved median survival of more 
than 20 months.27 However, a meta-analysis of 6286 patients in nine trials, including 
FOCUS and the French trial, shows that frailty is a dominant negative prognostic factor, 
with median survival of only 8·5 months in the subpopulation with WHO performance 
stats of 2.9 This ﬁ nding is entirely consistent with the survival recorded in FOCUS2, in 
which 134 of 459 (29%) patients were of performance status 2, and 324 of 459 (71%) 
were regarded as too frail to receive standard therapy (table 1).
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ﬁ nding was not signiﬁ cant; however, it also increased 
some toxic eﬀ ects and seemed to negatively aﬀ ect global 
QoL. So overall, was treatment with oxaliplatin 
worthwhile? OTU showed unequivocal evidence of 
overall beneﬁ t with oxaliplatin (table 3; ﬁ gure 3).
For the second factorial question, capecitabine has 
previously been shown to be non-inferior to ﬂ uorouracil,28 
and oral therapy is generally thought to be preferred by 
patients, either because of its convenience or because it 
is assumed to have low toxicity. However, although 
analysis of PFS and RR conﬁ rmed capecitabine’s eﬃ  cacy, 
we recorded increased toxicity and no evidence of 
improved QoL. And despite including a measure of 
whether treatment interferes with patients’ normal 
activities, the OTU scores for patients receiving 
capecitabine were not superior; indeed, they tended to 
favour ﬂ uorouracil, although this diﬀ erence was not 
signiﬁ cant (table 2B; ﬁ gure 3A). 
Guidelines from the US National Comprehensive 
Cancer Network recommend use of a comprehensive 
geriatric assessment (CGA) to guide decision making 
when considering chemotherapy in elderly patients.29,30 
However, there currently exists no evidence-based 
method to combine the many data items generated by 
the CGA into one decision about whether to oﬀ er 
chemotherapy, or which regimen to use. The 117-item 
geriatric assessment used in FOCUS2 was feasible in the 
oncology clinic, and we have started to identify which 
elements are of greatest value in prediction of the use of 
palliative chemotherapy. To develop a working predictive 
model will need cross-validation with other studies, but 
this approach oﬀ ers the potential to better inform 
oncologists’ discussions with patients. For example, a 
high predicted probability of a good OTU would support 
encouragement for chemotherapy; conversely, a high 
predicted probability of poor OTU (eg, in a patient with a 
high symptom score and widespread metastases) might 
help the oncologist and patient to consider with 
conﬁ dence the option of non-chemotherapy-based care.
New therapies now present new opportunities to 
develop treatments with few toxic eﬀ ects for frail elderly 
patients with advanced colorectal cancer. For example, 
investigators of the AGITG MAX trial,31 undertaken in 
patients of median age 68 years, reported signiﬁ cantly 
improved PFS without signiﬁ cant extra toxicity from the 
addition of bevacizumab to single-agent capecitabine. 
We encourage investigators to continue to design trials 
using appropriate low-toxicity treatments and patient-
centred assessment to expand the evidence base in this 
important specialty.
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